По следам SABCS 2022: TOP-16 исследований по раннему раку молочной железы, которые могут изменить нашу клиническую практику

Колядина И.В. По следам SABCS 2022: TOP-16 исследований по раннему раку молочной железы, которые могут изменить нашу клиническую практику. Современная Онкология. 2023;25(1):35–45.
DOI: 10.26442/18151434.2023.1.202053

© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.

________________________________________________

Kolyadina IV. Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review. Journal of Modern Oncology. 2023;25(1):35–45.
DOI: 10.26442/18151434.2023.1.202053

Читать PDF

Аннотация

Проведен анализ исследований, представленных на конференции SABCS 2022 по лечению рака молочной железы (РМЖ); выделены 16 наиболее интересных и значимых работ, которые доложены на устных или постерных сессиях. Представлены данные крупных рандомизированных и популяционных исследований, включая TAM-01 (роль адъювантной терапии тамоксифеном в дозе 5 мг при раке in situ), шесть исследований по хирургическому лечению раннего РМЖ, в том числе метаанализ по оценке влияния объема операции на показатели общей выживаемости, сравнение результатов таргетной лимфодиссекции и биопсии сигнальных лимфоузлов у больных после неоадъювантной системной терапии, анализ частоты локальных рецидивов после органосохраняющего лечения у больных мультицентричным РМЖ, а также влияние носительства патогенных вариантов мутаций генов ATM, BRCA1, BRCA2, CHEK2 и PALB2 на возникновение рака контрлатеральной молочной железы. Среди исследований по лекарственной терапии представлены 10-летние результаты APT trial, PEONY trial, результаты анализа TMC по различной роли добавления карбоплатина в режимы неоадъювантной химиотерапии у больных тройным негативным РМЖ моложе и старше 50 лет, рандомизированных клинических исследований по эскалации адъювантной эндокринотерапии в группах высокого риска рецидива (MonarchE и SWOG S1207), а также новые данные по когнитивной дисфункции после химиотерапии у больных в исследовании RxPONDER trial. Также заслуживают внимания анализы по лечению больных в особых клинических ситуациях: первые результаты исследования POSITIVE trial – оценка онкологических и акушерских исходов прерывания адъювантной эндокринотерапии с целью наступления беременности, анализ смертности мужчин с РМЖ за последние 20 лет, а также анализ влияния метилмалоновой кислоты на старческую слабость у больных ранним РМЖ.

Ключевые слова: рак молочной железы, конференция SABCS 2022, рак in situ, хирургическое лечение, таргетная лимфодиссекция, биопсия сигнального лимфоузла, адъювантная лекарственная терапия, неоадъювантная химиотерапия, осложнения химиотерапии, прерывание адъювантной эндокринотерапии с целью наступления беременности, рак молочной железы у мужчин, рак молочной железы у больных пожилого возраста

________________________________________________

A review of the studies presented at the SABCS 2022 conference on the treatment of breast cancer (BC) has been carried out; 16 of the most exciting and significant works reported at oral or poster sessions have been identified. Data from large randomized and population-based studies were presented, including TAM-01 (the role of adjuvant therapy with 5 mg tamoxifen for in situ cancer), six studies on the surgical treatment of early breast cancer, including a meta-analysis to assess the effect of surgery extent on overall survival, a comparison of the results of targeted lymph node dissection and biopsy of sentinel lymph nodes in patients after neoadjuvant systemic therapy, an analysis of the local relapse rate after breast-conserving surgery in patients with multicentric breast cancer, as well as the effect of carrier status of pathogenic variants of mutations in the ATM, BRCA1, BRCA2, CHEK2 and PALB2 genes on the occurrence of cancer of the contralateral breast. Among the systemic therapy studies, the 10-years results of APT trial, Peony trial were presented, as well as the results of the TMC analysis on the various roles of carboplatin addition in neoadjuvant chemotherapy regimens in patients younger and older than 50 years with triple-negative breast cancer, randomized clinical studies on the escalation of adjuvant endocrine therapy in high relapse risk groups (MonarchE and SWOG S1207), as well as new data on cognitive dysfunction after chemotherapy in patients in the RxPONDER trial. Also noteworthy are the reviews of treatment in special clinical situations: the first results of the POSITIVE trial (an assessment of the oncological and obstetric outcomes of interruption of adjuvant endocrine therapy for conception), an analysis of the mortality of males with breast cancer over the past 20 years, as well as an analysis of the methylmalonic acid effect on senile weakness in patients with early breast cancer.

Keywords: breast cancer, SABCS 2022 conference, in situ cancer, surgical treatment, targeted lymph node dissection, sentinel lymph node biopsy, adjuvant drug therapy, neoadjuvant chemotherapy, complications of chemotherapy, interruption of adjuvant endocrine therapy for conception, breast cancer in males, breast cancer in elderly patients

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. De Censi A. 10 year results of phase 3 trial of low-dose tamoxifen in noninvasive breast cancer. SABCS 2022, VJOncology.
2. Rajan KK. Оverall survival following breast conserving surgery and adjuvant radiotherapy compared with mastectomy for early stage breast cancer: a systematic review and meta-analysis. SABCS 2022.
3. Krug D. Pathologic complete response and breastconserving surgery are associated with improved prognosis in patients with early stage triple-negative breast cancer treated with neoadjuvant chemotherapy. SABCS 2022, PD15-06 spotlight poster discussion 15.
4. Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. Breast Care (Basel). 2021;16(2):135-43. DOI:10.1159/000516114
5. Kuemmel S, Heil J, Rueland A, et al. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. Ann Surg. 2022;276(5):e553-62. DOI:10.1097/SLA.0000000000004572
6. Montagna G, Mrdutt M, Sun SX, et al. The OPBC-04/EUBREAST-06/OMA Study Oncological Outcomes Following Sentinel Lymph Node Biopsy (SLNB) or Targeted Axillary Dissection (TAD) in Breast Cancer Patients Downstaging From Node Positive To Node Negative with Neoadjuvant Chemotherapy. SABCS 2022.
7. Boughey JC. Alliance ACOSOG Z11102: impact of breast conservation therapy on local recurrence in pts with MIBC. SABCS 2022, VJOncology.
8. Graeser M, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887-92. DOI:10.1200/JCO.2008.19.9430
9. Yadav S, Boddicker NJ, Na J, et al. GS4-04 Population-based Estimates of Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2. SABCS 2022.
10. Tolaney S, Barry W, Guo H, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol. 2017;35(15):511. DOI:10.1200/JCO.2017.35.15_suppl.511
11. Tolaney S, Tarantino P, Graham N, et al. PD18-02 Adjuvant paclitaxel and trastuzumab trial (APT) for node-negative human epidermal growth factor receptor 2-positive (HER2+) breast cancer: final 10-year analyses. SABCS 2022.
12. Shao Z, Pang D, Yang H, et al. Final analysis of the phase III PEONY trial: long-term efficacy and safety of neoadjuvant–adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER2-positive early or locally advanced breast cancer. SABCS 2022.
13. Gupta S, Nair NS, Hawaldar R, et al. GS5-01 Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. SABCS 2022.
14. Johnston S, Toi M, O'Shaughnessy J, et al. GS1-09 Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. SABCS 2022.
15. Chavez-MacGregor M, Miao J, Pusztai L, et al. GS1-07 Results from a phase III randomized, placebocontrolled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207. SABCS 2022.
16. Kang I, Forschmiedt JK, Loch MM, et al. Patient-reported Cognitive Impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status. SABCS 2022.
17. Partridge AH, Niman SM, Ruggeri M, et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13). SABCS 2022.
18. Leone J, Hassett MJ, Freedman R, et al. PD6-08 Mortality risks over 20 years in men with stage I–III hormone receptor-positive breast cancer. Cancer Res. 2023;83(Suppl. 5):PD6-08.
19. Fox S, Speirs V, Shaaban A. Male breast cancer: an update. Virchows Arch. 2022;480(1):85-93. DOI:10.1007/s00428-021-03190-7
20. Colleoni M, Sun Z, Price KN, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34(9):927-35. DOI:10.1200/JCO.2015.62.3504
21. Leone JP, Leone J, Zwenger AO, et al. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study. Am J Clin Oncol. 2019;42(7):588-95. DOI:10.1097/COC.0000000000000563
22. Wu Q, Hatse S, Kenis C, et al. PD6-03 Serum methylmalonic acid concentrations at breast cancer diagnosis strongly correlate with frailty: a retrospective cross-sectional study. SABCS 2022. Cancer Res. 2023;83(Suppl. 5):PD6-03.
23. Boutin M, Presse N, Martineau T, et al. Mass spectrometry analysis of urinary methylmalonic acid to screen for metabolic vitamin B12 deficiency in older adults. Bioanalysis. 2020;12(10):693-705. DOI:10.4155/bio-2020-0106
24. Gomes A, Ilter D, Low V, et al. Age-induced accumulation of methylmalonic acid promotes tumour progression. Nature. 2020;585(7824):283-7. DOI:10.1038/s41586-020-2630-0

________________________________________________

Авторы

И.В. Колядина*

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия; ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России, Москва, Россия
*irinakolyadina@yandex.ru

________________________________________________

Irina V. Kolyadina*

Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*irinakolyadina@yandex.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.